Loading...
•
Jun 30, 2022
BioMarin Q2 2022 Earnings Report
BioMarin announced record revenues and increased full-year 2022 top and bottom-line guidance.
Key Takeaways
BioMarin announced record revenues in the second quarter of 2022, driven by strong growth of VOXZOGO and solid contributions from other franchises. Total revenues reached $533.8 million, a 6% increase compared to the same period in 2021. The company increased its full-year 2022 top and bottom-line guidance.
Total Revenues for the second quarter of 2022 were $533.8 million, an increase of 6% compared to the same period in 2021.
VOXZOGO commercial sales drove revenue growth due to new patients initiating therapy in Europe and the U.S.
GAAP Net Income and Non-GAAP Income increased by $14.8 million and $11.6 million, respectively, for the second quarter of 2022 compared to the same period in 2021.
BioMarin expects that ROCTAVIAN for the Treatment of Severe Hemophilia A Will Be Approved in Europe in the Third Quarter; Re-Submission of Biologics License Application (BLA) in the U.S. Planned for September 2022
BioMarin
BioMarin
BioMarin Revenue by Segment
Revenue by Segment
VOXZOGO Revenue
CapyFin.comVIMIZIM Revenue
CapyFin.comNAGLAZYME Revenue
CapyFin.comPALYNZIQ Revenue
CapyFin.comALDURAZYME Revenue
CapyFin.comBRINEURA Revenue
CapyFin.comKUVAN Revenue
CapyFin.com Forward Guidance
BioMarin increased full-year 2022 top and bottom-line guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income